Sarepta shares soar as Duchenne gene therapy shows promise
(Reuters) - Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Gene Therapy | Genetics | Health | Muscular Dystrophy | Reflex Sympathetic Dystrophy | Study